If you have cancer, you expect to see an oncologist, but if you have heart failure you may or may not see a cardiologist.

Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Those people have a greater risk of death compared to those who see a cardiologist at least once a year. Even ...

People with irregular sleep schedules had a 26% higher risk of major cardiovascular events, even if they got the recommended ...

CellProthera will tech transfer to CELLforCURE by SEQENS this year, with plans to produce clinical batches starting in 2026.

Heart failure represents one of the most significant global health challenges, affecting millions worldwide and requiring subsequent hospitalization for many patients due to complications.

Broken heart syndrome” carries a significant risk of death and serious complications. Although the condition appears to be ...

Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to ...

This is the reality of congestive heart failure, a condition affecting approximately 6 million Americans, with 550,000 new cases diagnosed annually. Despite its ominous name, heart failure does ...

Cognitive decline is a common side effect of heart failure, new research published in Circulation: Heart Failure found. Specifically, researchers discovered a link between a heart failure ...

CellProthera says it chose CELLforCURE by SEQENS as its CDMO for the quality of its infrastructure, equipment, and expertise of its team.